STADA and SBP Group launch biosimilars partnership
German generics and consumer healthcare major STADA Arzneimittel (SAZ: Xetra) and China-based group SBP Group, through its core innovative pharmaceutical subsidiary CTTQ, today announced a strategic biosimilars partnership designed to significantly broaden patient access to high‑value biological medicines in key markets.
The collaboration comprises CTTQ developing, manufacturing and supplying biosimilar candidates for which STADA will hold the marketing authorizations and have exclusive sales and marketing rights in the European Union, Switzerland, the UK and the Commonwealth of Independent States (CIS). Furthermore, STADA will hold options for the USA and Gulf Cooperation Council (GCC) member states.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
| Headless Content Management with Blaze